Endo International +2.1% after JPM conference slides

• The company reaffirms full-year guidance: revenue of $3.87B-$4.03B, adjusted gross margin about 60%, and adjusted EPS of $4.50-$4.80.
• Also part of the talking points: Statistically significant Phase IIb results for Xiaflex in cellulite, key FTF launches of generic Seroquel and generic Zeita, and progress on the strategic review.
• Presentation slides
• The presentation begins at 1:30 ET.
• ENDP +2.1%
• #JPM17